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ABSTRACT 35 
Objectives: The public and patients are primary contributors and beneficiaries of  pandemic-relevant 36 
clinical research. However, their views on research participation during a pandemic have not be n 37 
systematically studied. We aimed to understand public views regarding participation n cl nical research 38 
during a hypothetical influenza pandemic.  39 
Study design: International cross-sectional survey 40 
Methods: We surveyed the views of nationally representative samples of people in Belgium, Poland, 41 
Spain, Ireland, United Kingdom, Canada, Australia and New Zealand, using a scenario-based 42 
instrument during the 2017 regional influenza season. Descriptive and regression analyses were 43 
conducted.  44 
Results: Of the 6804 respondents, 5572 (81·8%) thought pandemic-relevant research was important 45 
and 5089 (74·8 %) thought “special rules” should apply to make this research feasible. Respondents 46 
indicated willingness to take part in lower-risk (4715, 69·3%) and higher-risk (3585 52·7%) primary 47 
care, and lower-risk (4780, 70·3%) and higher-risk (4113, 60·4 %) Intensive Care Unit (ICU) study 48 
scenarios. For primary care studies, most (3972, 58·4%) participants preferred standard enrolment 49 
procedures such as prospective written informed consent, but 2327 (34·2%) thought simplified 50 
procedures would be acceptable. For ICU studies, 2800, (41·2%) preferred deferred consent and 2623 51 
(38·6%) preferred prospective third-party consent.  Greater knowledge about pandemics, trust in a 52 
health professional, trust in government, therapeutic misconception and experience of ICU as a patient 53 
or carer predicted increased willingness to participate in pandemic-relevant research. 54 
Conclusions: Our study indicates current public support for pandemic-relevant clinical research. 55 
 3 
Tailored information, and initiatives to advance research literacy and maintain trust are required to 56 
support pandemic-relevant research participation and engagement.  57 
 58 
Highlights 
 There is strong public support for pandemic-relevant clinical research initiatives. 
 
 Willingness to participate in research and to be enrolled under more permissive approaches 
depends on the type of research and key participant factors. 
 
 Knowledge about pandemics, trust in professionals and in government, therapeutic 
misconception and experience of critical illness influence willingness to participate in 
pandemic-relevant research. 
 
 
 59 
INTRODUCTION 60 
The centenary of the 1918 Influenza pandemic presents a stark reminder of global vulnerability to 61 
infectious disease health threats1. One third of the global population became infected, resulting in 50-62 
100 million deaths. Advances in science, technology, medicine, health systems, and coordinati n 63 
mechanisms have strengthened global preparedness to respond to future pandemics2.  However, as 64 
evidenced during the 2009 H1N1 pandemic, insufficient capability to rapidly generate evidence through 65 
clinical research implemented during the pandemic itself results in significant gaps in our preparedness 66 
for pandemics. Emerging data from clinical research is vital to inform public health responses, for 67 
example, through robust disease severity assessments that account for clinical presentation across the 68 
illness severity spectrum3 and to inform clinical management guidelines4,5. During the H1N1 pandemic, 69 
clinical management guidelines were necessarily based on expert opinion as scientific evidence was not 70 
available. Expert guidance recommended use of oseltamivir, for example, which was widely prescribed 71 
to patients with acute respiratory infections at significant cost to healthcare systems. However, the 72 
opportunity to evaluate the clinical and cost effectiveness of oseltamivir in p ospective trials was 73 
missed, as intervention studies could not be delivered in time to enrol patients during the pandemic 74 
itself3 and little evidence was generated about the prudence of stockpiling these antivial gents.  75 
 4 
Oseltamivir is now widely regarded as standard of care for the treatment of patients t higher risk of 76 
complications from influenza, despite no available prospective trial evidence to support its use in 77 
severely ill patients6, and this now presents an ethical dilemma for its evaluation in a randomised 78 
placebo-controlled trial.  The newly launched WHO global influenza strategy includes research and 79 
innovation for diagnostics, vaccines and treatments as one of four priorities for pandemic preparedness7. 80 
 81 
There are multiple and persistent political, contractual, administrative, logistic and regulatory 82 
challenges that must be navigated for clinical studies to be open for recruitment in time to enrol patients 83 
during peak pandemic waves. One approach to unblocking these barriers involves pre-funding active 84 
clinical research networks, such as those in the Platform foR European Preparedn ss Against (Re-85 
)emerging Epidemics (PREPARE). PREPARE conducts multi-site, pan-European clinical studiesin 86 
community, hospital and critical care settings that address important study questions during inter-87 
pandemic periods of seasonal influenza. These research active networks would re-orientate their inter-88 
pandemic research activities in the event of a public health emergency, thereby reducing the time needed 89 
to recruit and prepare research sites. PREPARE clinical trials employ novel adaptive platform designs 90 
with response adaptive randomisation that shortens the time to identifying a superior performing 91 
treatment8-10 These trials evaluate the comparative effectiveness of routinely available treatments and 92 
allow for rapid inclusion of an additional trial arm to evaluate novel therapeutics if these become 93 
available.   94 
 95 
The success of these initiatives, however, is dependent on research and clinical staff being willing to 96 
enrol patients11, and patients being willing to participate. Research enrolment processes that are time 97 
consuming, unnecessarily detailed and burdensome will deter patient enrolment, even among those 98 
patients who would be otherwise willing to participate12 Existing enrolment models will likely be ill 99 
suited to the highly pressured conditions of pandemic-relevant research13 nd less burdensome, risk 100 
proportionate consent models may be acceptable. In addition, residual clinical samples e.g. nasal swabs 101 
and blood samples, collected and stored after clinical procedures would be an important resource for 102 
pandemic relevant ID research and development of new diagnostic tests. Currently these samples are 103 
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not routinely stored, and consent for using and sharing samples and associated clinical data for research 104 
and test development, vary between countries, presenting a challenge to multi site, pan-European 105 
research efforts14,15.  106 
 107 
As the primary contributors and potential beneficiaries of pandemic-relevant research, patients and the 108 
public are key, and often underrepresented, stakeholders in research preparedness. While these groups 109 
have been consulted for public health pandemic planning16-19, there have been no systematic efforts to 110 
capture their views relevant to participation in clinical research conducted during an influenza 111 
pandemic. Further, understanding public views should inform preparations for appropriate, 112 
proportionate regulation and oversight of pandemic-relevant research. To advance preparedness to 113 
deliver a clinical research response in a pandemic scenario, we aimed to address this gap.  114 
METHODS  115 
We conducted an international cross-sectional survey involving a nationally representative sample of 116 
respondents in each of Belgium, Spain, Poland, Ireland, the United Kingdom, Canada, Australia and 117 
New Zealand. These countries were selected as involved with or affiliated to the PREPARE consortium. 118 
European member states were selected to include a country from each of northern, southern, eastern 119 
and western Europe, as defined by the United Nations macro geographical regions20. These countries 120 
were also included in qualitative work that informed the survey development. Respondents aged 18-121 
65years in each country, except Poland (age range 18-59 years), were invited via a pre-recruited online 122 
panel hosted by the Ipsos Group. Ipsos Group is a market research company that regularlyconducts 123 
online research for academic institutions. This group administered data collection. Ipsos Group 124 
generated quotas on age, gender, employment status and region in all countries, setting targe s based on 125 
the most up-to-date census data to ensure that the sample profile was in-line with the nationally 126 
representative proportions in that country. Ipsos Group addressed any small imbalances in the sample 127 
by weighting the final data set. All analyses used weighted data.  128 
 129 
Data collection 130 
 6 
Data were collected via an online survey in March 2017 in Northern hemisphere countries and in July 131 
–Aug 2017 in Southern hemisphere countries, to coincide with regional influenza seasons. Potential 132 
respondents were invited to take part in the survey in batches, in order to contr l the sample profile. 133 
Data collection was planned to continue until the target sample size (850 per country, 6800 total) was 134 
reached. The selection of the sample size was pragmatically driven and involved balancing the size of 135 
the sample that we would need to identify differences between countries with the cost of administering 136 
the survey via Ipsos Group across multiple countries.  137 
 138 
Data collection instrument 139 
We developed a scenario-based instrument in which respondents w re asked to imagine there is an 140 
influenza pandemic and they were being i vited to participate in clinical research in primary and critical 141 
care settings (Box 1; supplementary material). In both scenarios, respondents were asked for their views 142 
on taking part in a low and higher risk clinical trial, and to indicate their preferences related to 143 
notification and consent for participating in the low-risk study. Low risk scenarios involved comparison 144 
of two medications that were routinely used in everyday clinical practice. Higher r sk scenarios involved 145 
patients receiving either a new medication that had passed safety testing or a placebo. Finally, 146 
respondents were asked for their views on the acceptability of any surplus clinical samples (blood or 147 
swabs for example), that had been collected as part of clinical care, being subsequently used for 148 
pandemic research, without explicit patient consent being solicited for their use. We used illustrations 149 
to enhance brief explanations of key concepts.   150 
To develop the survey tool, we consulted the public in four European countries12 to identify content 151 
domains for the survey (July-November 2015). We reviewed relevant literature5,13,21-23 and sought 152 
expert opinion to prioritise content domains. We also identified demographic and attitu inal variables12 153 
that might explain willingness to participate in pandemic-relevant research. These variables included 154 
age, being a parent, having had experience of critical illness (as a patient, family me ber or close friend 155 
of a patient) and therapeutic misconception24 (i.e. research participants holding a belief that research 156 
usually or always results in individual benefits as opposed to understanding that the purpose of research 157 
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is to produce generalizable findings relevant to a population). T  refine the wording and response format 158 
of the survey questions, we conducted cognitive interviewing using the think aloud technique25. 159 
Changes to the survey were made iteratively, at three time points. The data collection instrument was 160 
circulated for comment to colleagues in Belgium, Spain, Poland, Australia and New Zealand to ensure 161 
applicability to their healthcare context. The final version of the instrument was ranslated into Flemish, 162 
French, Spanish and Polish and back translated to ensure accuracy. Before the survey was distributed, 163 
a small segment of the overall target group of respondents completed the survey and data were reviewed 164 
to identify any difficulties. No changes were required following this soft launch.  165 
Analysis  166 
We combined survey responses into three categories (strongly disagree/disagree, neutral and 167 
agree/strongly agree) and ran ordinal regression models to xamine demographic and attitudinal factors 168 
predictive of respondent willingness to participate in primary care and ICU studies and willi gness for 169 
routinely collected clinical samples to be used for pandemic-relevant research. To identify suitable 170 
candidate variables for regression models, we first conducted univariate associations using a chi squared 171 
test. Candidates that were significant at p<0·01 in univariate analyses were then included. Factors that 172 
account for how participants would like to be consented were examined in an exploratory post-hoc 173 
analysis using a logistic regression. To explore whether any factors predicted w llingness to engage 174 
with an alternate approach to consent, we created a binary variable that classified re pondents as only 175 
willing to consider the standard “Opt in” consent models (box 1) versus willing to consider any of the 176 
other options. This variable was used as the outcome in logistic regression models that included only 177 
those participants that expressed willingness to take part in each scenario study. In order to assess the 178 
impact of missing data at baseline and possible bias arising from data not being missi  completely at 179 
random (MCAR) the regression models were reanalysed using multiple imputation with chained 180 
equations, which is valid under a less restrictive missing at random (MAR) assumption. The results did 181 
not differ substantially from the complete case analysis, which suggests there is not substantial bias due 182 
to missing data. Data were analysed using STATA version 15.0. 183 
 184 
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Ethics, consent, sponsorship, ethical treatment of human subjects 185 
Participants gave voluntary consent for their involvement in the survey. All data were held in 186 
accordance with the Data Protection Act.  187 
 188 
RESULTS 189 
A total of 6804 members of the public completed the survey: 850 in each of Ireland, Spain, Belgium, 190 
and New Zealand, and 851 in each of Poland, the United Kingdom, Australia and Canada (t ble 1). 191 
Response rates were not calculated due to the quota sampling technique used.  192 
 193 
Public attitudes to clinical research  194 
Respondents considered it important that medical research is conducted during an influenza pandemic 195 
(5572, 81·9%) and that special rules should apply to make it easier to do pandemic-rel vant research 196 
(5089, 74·8%). Results were similar across countries, with the exception of respnd nts from Poland 197 
who indicated lower agreement with the importance of medical research in a pa demic (538 of 831, 198 
64·7%).  199 
 200 
Primary Care: willingness to participate in low and higher risk scenarios  201 
A majority of respondents were willing to take part in both the lower risk (4715, 69·3%) and higher 202 
risk (3585, 52·7%) primary care study (Figures 1a and 1b). A small proportion of respondents were 203 
unwilling to take part in the low risk scenario (792, 11·6%), and 1466 (21·6%) respondents were 204 
unwilling to take part in the higher risk cenario. The differences in proportion endorsing each response 205 
varied significantly by country (χ2p<0·001) for both the low and high-risk scenarios (figures 1a and 1b 206 
and table 2). Being female (compared with male) was associated with decreased willingness to take part 207 
in the high-risk primary care scenario (table 2). For both low and higher risk primary care scenarios, 208 
the less knowledge respondents had about pandemics, the lower their reported willingness to take part. 209 
Having had ICU experience, trust in a doctor, trust in the government and therapeutic misconception 210 
were variables associated with greater willingness to participate in both scenarios (table 2).  211 
 212 
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Primary care: notification and consent preferences for enrolment to low risk CER scenario 213 
Of those respondents willing to take part in the low risk primary care scenario (4715, 69·3%), the 214 
majority preferred standard opt-in consent procedures as a first choice (2742, 58·2%), although nearly 215 
a third (1371, 29·1%) selected opt-out consent as a first choice (table 3). Automatic inclusion was the 216 
least preferred option (461, 9·79%).  Of those respondents who indicated willingness to take part in the 217 
primary care study, respondents from Spain (compared with the UK) were less likely to accept 218 
enrolment under alternate consent models (table 4). A low level of pandemic knowledge was associated 219 
with non-acceptance of enrolment under alternative consent models, while having had ICU experience 220 
and having greater trust in government were variables associated with acceptance of  enrolment under 221 
alternate consent models (table 4). 222 
 223 
ICU: willingness to participate in low and higher risk scenarios  224 
The majority of respondents expressed willingness to take part in both the lower risk (4780, 70·3%) 225 
and higher risk (4113, 60·4%) ICU studies (ICU studies (Figures 2a and 2b). A χ2 test comparing 226 
proportion endorsing each response against country was statistically significant (p<0·001) for both the 227 
low and high-risk scenarios. Older age groups were associated with being more willing to participate 228 
in the higher risk ICU scenario (table 5).  A low level of pandemic knowledge was associated with 229 
being less willing to participate in both ICU research scenarios. Having had ICU experience, having 230 
greater trust in a doctor, greater trust in the government and higher levels of therapeutic misconception 231 
were all associated with being more willing to take part in both ICU scenarios (table 5).  232 
 233 
ICU: notification and consent preferences for enrolment to low risk CER scenario 234 
Of those respondents willing to take part in the low risk ICU scenario (4780, 70·3%), deferre  consent 235 
given either by a doctor (1345, 28·1%) or a family member (958, 20·0%) were the first choice 236 
preferences (table 6). Prospective “opt-in” informed consent procedures was the first choice preference 237 
for 35·3% respondents (n=1686). Only 592 (12·4%) respondents indicated that they preferred automatic 238 
inclusion (i.e. without consent being provided). Of the respondents who were willing to take part in the 239 
ICU study, those that had some experience of ICU, were living with someone rather th n alone, and 240 
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had greater trust in government, were more likely to engage with alternative consent mod ls for the low 241 
risk ICU scenario (table 7).  242 
 243 
Attitudes to use of surplus routinely collected clinical samples for research 244 
5256 (77·2%) of respondents indicated that they would be willing for any surplus of their routinely 245 
collected clinical samples to be used for pandemic relevant studies during an outbreak itself, and only 246 
slightly fewer 4871 (71·6%) were happy for them to be used after n outbreak without additional 247 
consent being sought. 4940 72·6% were willing for their genetic materials to be used for research, and 248 
3869 (56·9%) were willing for their samples to be used for non pandemic-relevant studies. A trend for 249 
age was observed, with older respondents across each age category being more likely to accept their 250 
excess routinely collected clinical samples being used for pandemic-relevant reserch (table 8). Greater 251 
trust in a doctor, greater trust in government and higher levels of therapeutic misconception were 252 
associated with willingness for clinical samples to be used for research.  253 
 254 
DISCUSSION  255 
Members of the public across eight OECD countries support medical research being delivere  in 256 
response to a pandemic of influenza and a majority of respondents would be willing to take part in 257 
medical research in both primary and critical care settings. While the majority of respondents wanted 258 
to provide prospective informed consent for enrolment to primary care studies, a substantial minority 259 
would consider alternatives. Deferred consent was acceptable to the majority of resp ndents for 260 
enrolment to ICU studies. Pandemic knowledge, trust in health professionals, in government, and 261 
experience of critical illness influence indicative willingness to participate. Therapeutic misconception 262 
and wanting access to novel therapeutics through trial participation were also predictive of w llingness 263 
to participate. A majority of respondents were also supportive of their surplus clinical samples being 264 
used for research without specific consent.  265 
 266 
A strength of this study is the extensive piloting and refinement used in the development of the survey 267 
instrument . We also used images to enhance explanations of core concepts. However, we were unable 268 
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to fully assess participant interpretation of these ideas and it is possible that some concepts were not 269 
uniformly understood. A limitation of the instrument is that it employed hypothetical scenarios and 270 
respondent views might change with actual experience. However, respondents’ expre sed willingness 271 
to participate in research has been shown to provide a moderate estimate of actual participation26. We 272 
do not consider our findings to be a substitute for involvement of the public or for good participatory 273 
practice27 when planning pandemic-relevant studies. Our survey used quota sampling, a non-274 
probabilistic sampling method, and the appropriateness of drawing population wide inferences using 275 
this approach has been questioned by some. This was an online survey that required spon ents to 276 
access the Internet to complete it. Given the high proportion of internet pe ration in the countries 277 
surveyed in 201728, we do not anticipate the digital divide to have impacted on representativeness of 278 
the sample. Our findings may be influenced by self-selection bias in that respondents had signed up to 279 
an online panel. We are also unable to evaluate the impact of potential nonresponse bias. The survey 280 
addressed complex ideas that may not have been uniformly understood. Despite our efforts to address 281 
this by using cognitive interviewing in designing the survey, varying interpretation of survey questions 282 
represents potential for non-sampling error. Respondents were from countries i  the OECD as these 283 
were relevant to PREPARE clinical studies and are vulnerable to influenza pandemics. Lower and 284 
Middle Income Countries bear the greatest burden of infectious disease outbreaks and findings from 285 
our survey do not inform research preparedness in these regions.  286 
 287 
Recent debates regarding comparative effectiveness research have highlighted the inflexibility of 288 
standard recruitment processes and argued for more adaptable enrolment protocols in circumstances 289 
where informed consent may not be possible, or ethically necessary29-31.  Others have also identified a 290 
substantive minority of respondents supportive of alternate consent procedures for low risk pragmatic 291 
trials32-34. However, our study is the first to consider this question in the context of a pandemic. Current 292 
ethical guidelines35,36 and new regulations37 offer some guidance for emergency research and endorse 293 
adapted models of enrolment (e.g. deferred consent) where patents lack capacity to consent them lves. 294 
Where patients have capacity (for example, enrolment to a primary care trial), even in the event of a 295 
public health emergency, current guidelines35,36 endorse prospective informed consent process 296 
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regardless of risk through trial participation. Findings from our survey support this approach. In 297 
contrast, experience from public involvement in the design of a pre-positioned clinical trial protocol in 298 
the UK found that alternatives (verbal consent or opt-out consent) were acceptable21. This study was 299 
unable to adopt these alternate consent procedures however as they were considered not acceptable 300 
under current legislation governing clinical trials of investigative m dicinal products (CTIMPs) in 301 
Europe.  302 
 303 
This tension between pragmatic and acceptable informed consent processes and guiding legislation 304 
represents a notable bottleneck in the viability of clinical research being conducted in a public health 305 
emergency.  In Europe, the forthcoming Clinical Trials Regulation (No 536/2014)37 that will govern the 306 
conduct of CTIMPs in European Union member states recognises the need for expediting clinical trial 307 
applications for approval in a public health emergency, however, no mention is made of acc ptable 308 
adaptations to consent procedures that are proportionate to study risk or to the context of crisis in the 309 
event of a pandemic. This legislation includes a new category of “low intervention” clinical study, 310 
recognising that not all clinical trials present the same degree of risk to research participants and 311 
simplified informed consent procedures are deemed acceptable for enrolment to “low intervention” 312 
cluster trials conducted in a single member state (article 30). However this does not extend to pan-313 
European or individually randomised trials.  314 
 315 
Similar tensions exist in debates about residual clinical samples being used for pandemic-relevant 316 
research purposes. Like others who have considered this question38,39 albeit in a non pandemic context, 317 
we identified public willingness to donate excess clinical samples for resea ch. These findings require 318 
further consideration in relation to consent requirements for the use of residual clinical samples and 319 
associated data14. For pandemic-relevant research, sample and data sharing across countries will b  320 
important and full de-identification of patient data may not be possible, particularly at the early stages 321 
of an outbreak. The General Data Protection Regulation (GDPR), legislation that aims to harmonise 322 
and strengthen the rules for protecting dividual’s privacy rights within the EU may inadvertently 323 
create barriers to this process. Clarity regarding interpretation of new EU legislation and the 324 
 13 
implications for pandemic relevant studies is needed if the significant investment in establishing a 325 
clinical research infrastructure to respond to these public health threats can be fully realised.  326 
 327 
Our study found strong support for pandemic-relevant research and a need for wider debate about more 328 
permissive approaches to enrol patients into low risk comparative effectiveness r s arch in this context. 329 
Experience of critical illness, trust in doctors and in government, and knowledge about p ndemics were 330 
key explanatory factors. These insights should inform communication and recruitment plan ing for 331 
delivering a pandemic research response, for example, in the PREPARE consortium.  Active efforts to332 
engage and involve the public are required in order to build knowledge about pandemics and about the 333 
value of research and what research participation in research involves. Key messages, such as 334 
uncertainty regarding the superiority of the experimental agent and the purpose of research to produce 335 
generalizable results rather than to confer individual benefit, and the distinction between research 336 
participation and receipt of clinical care, should be well communicated. For patients, attention to how 337 
participation in research is framed, for example, in the wording of participant information sheets can 338 
mitigate risk of therapeutic misconception40. For the wider public, initiatives that open the way to 339 
dialogue and deliberation and that that build research literacy are needed, for example through citizen 340 
science and tailored engagement initiatives across communities. Invariably, an infectious disease 341 
pandemic will bring with it an epidemic of fear, at which point it will be too late to address these gaps. 342 
The research community must be ready to counter the rumours and conspiracy theories that will 343 
inevitably circulate with a response that champions the contribution of scientific evidence n protecting 344 
health and saving lives.  345 
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Figure 1a: Willingness to take part in low risk primary care scenario 477 
 478 
Figure 1b: Willingness to take part in higher risk primary care scenario 479 
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Figure 2a Willingness to take part in low risk ICU scenario 481 
 482 
Figure 2b Willingness to take part in higher risk ICU scenario  483 
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Box 1: Consent options provided for primary care and Intensive Care Unit Comparative 485 
Effectiveness Research scenarios  486 
 
For both low-risk scenarios, respondents were informed that ‘information about the study would be circulated 
via newsletters, posters, and media outlets’.  
 
Primary care CER scenario: comparison of two routinely used medications 
 Automatic enrolment:  You would be automatically included in the study. When being prescribed the 
medication, the doctor wouldn’t mention the research. 
 Opt-out: Sign me up automatically, but remind me of the study when I get the medicine and give me a 
chance to opt out. When being prescribed the medication, the doctor would give you more information 
and you would have a chance to opt out of the study if you wished. 
 
 Opt-in: Ask me to sign up when I am due to get the medicine. When being prescribed the medication, the 
doctor would explain the study and a researcher would ask you to sign up (prospective informed consent) 
 
ICU CER scenario: comparison of two routinely available treatments  
 Deferred consent (family): Include me immediately, family decides later if that’s ok. You would be 
automatically included in the study. As soon as they could be contacted, a close family member would 
then decide whether or not you should stay included in the study.  
 
 Deferred consent (doctor): Include me immediately, doctor decides later if that’s ok. You would be 
immediately included in the study. A hospital doctor who is not a researcher in the study but who knew 
about it would decide whether or not you should stay included in the study.   
 
 Automatic enrolment: Include me immediately, don’t ask my or anyone’s consent. You would be 
automatically included in the study without asking your consent or anyone cons nting on your behalf. 
 
 Opt-in: Don’t include me until a family member says it’s ok. You would not be included in the study until 
a close family member could be contacted to make that decision on your behalf (prospective informed 
consent provided by a third party if the patient lacks capacity) 
 
487 
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Table 1: Demographic characteristics of the sample 488 
Characteristic 
 
UK  
(N=851) 
Australia 
(N=851) 
New Zealand 
(N=850) 
Ireland 
(N=850) 
Canada 
(N=851) 
Spain 
(N=850) 
Belgium 
(N=850) 
Poland 
(N=851) 
Overall 
(N=6804) 
Age           
18-24 132 (15·51%) 105 (12·34%) 110 (12·94%) 117 (13·76%) 110 (12·93%) 92 (10·82%) 117 (13·76%) 133 (15·63%) 916 (13·46%) 
25-34 181 (21·27%) 190 (22·33%) 165 (19·41%) 197 (23·18%) 173 (20·33%) 183 (21·53%) 172 (20·24%) 230 (27·03%) 1,491 (21·91%) 
35-44 185 (21·74%) 197 (23·15%) 191 (22·47%) 208 (24·47%) 173 (20·33%) 221 (26·00%) 183 (21·53%) 196 (23·03%) 1,554 (22·84%) 
45-54 179 (21·03%) 188 (22·09%) 201 (23·65%) 176 (20·71%) 213 (25·03%) 194 (22·82%) 196 (23·06%) 185 (21·74%) 1,532 (22·52%) 
55-65 (55-59 Poland only) 174 (20·45%) 171 (20·09%) 183 (21·53%) 152 (17·88%) 182 (21·39%) 160 (18·82%) 182 (21·41%) 107 (12·57%) 1,311 (19·27%) 
Gender           
Male 429 (50·41%) 422 (49·59%) 383 (45·06%) 407 (47·88%) 408 (47·94%) 425 (50·00%) 425 (50·00%) 428 (50·29%) 3,327 (48·90%) 
Employment status:          
Employed full-time  444 (52·17%) 374 (43·95%) 374 (44·00%) 438 (51·53%) 496 (58·28%) 377 (44·35%) 420 (49·41%) 483 (56·76%) 3406 (50·06%) 
Employed part-time 144 (16·92%) 166 (19·51%) 152 (17·88%) 80 (9·41%) 108 (12·69%) 83 (9·76%) 93 (10·94%) 70 (8·23%) 896 (13·17%) 
Self-employed 58 (6·82%) 47 (5·52%) 84 (9·88%) 48 (5·65%) 70 (8·23%) 52 (6·12%) 35 (4·12%) 54 (6·35%) 448 (6·58%) 
Unemployed, job seeking 34 (4·00%) 60 (7·05%) 58 (6·82%) 66 (7·76%) 39 (4·58%) 149 (17·53%) 53 (6·24%) 64 (7·52%) 523 (7·69%) 
Unemployed not job seeking 82 (9·64%) 98 (11·52%) 95 (11·18%) 84 (9·88%) 61 (7·17%) 55 (6·47%) 95 (11·18%) 58 (6·82%) 628 (9·23%) 
Retired 50 (5·88%) 58 (6·82%) 34 (4·00%) 46 (5·41%) 58 (6·82%) 39 (4·59%) 70 (8·24%) 40 (4·7%) 395 (5·81%) 
Student / full- time education 30 (3·53%) 38  (4·47%) 44 (5·18%) 73 (8·59%) 13 (1·53%) 79 (9·29%) 71 (8·35%) 51 (5·99%) 399 (5·86%) 
Other 9 (1·06%) 10 (1·18%) 9 (1·06%) 15 (1·76%) 6 (0·71%) 16 (1·88%) 13 (1·53%) 31 (3·64%) 109 (1·6%) 
Education          
No completed education 3 (0·35%) 2 (0·24%) 6 (0·71%) 3 (0·35%) 2 (0·24%) 6 (0·71%) 15 (1·76%) 4 (0·47%) 41 (0·6%) 
Primary education  4 (0·47%) 3 (0·35%) 3 (0·35%) 6 (0·71%) 0 (0%) 26 (3·06%) 12 (1·41%) 7 (0·82%) 61 (0·9%) 
Lower secondary  168 (19·74%) 93 (10·93%) 92 (10··82%) 37 (4·35%) 19 (2·23%) 111 (13·06%) 93 (10·94%) 9 (1·06%) 622 (9·14%) 
Upper secondary  254 (29·85%) 124 (14·57%) 126 (14·82%) 124 (14·59%) 143 (16·80%) 162 (19·06%) 270 (31·76%) 353 (41·48%) 1,556 (22·87%) 
Post-secondary vocational  23 (2·7%) 263 (30·9%) 217 (25·53%) 162 (19·06%) 304 (35·72%) 127 (14·94%) 29 (3·41%) 91 (10·69%) 1,216 (17·87%) 
Tertiary education  394 (46·30%) 360 (42·31%) 375 (44·11%) 510 (60%) 377 (44·30%) 410 (48·23%) 427 (50·24%) 378 (44·42%) 3231 (47·49%) 
Prefer not to say 5 (0·59%) 6 (0·71%) 31 (3·65%) 8 (0·94%)  6 (0·71%) 8 (0·94%)  4 (0·47%) 9 (1·06%) 77 (1·13%) 
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Table 2: Factors predictive of willingness to participate in low and higher risk pandemic-relevant 
studies in primary care 
Variable             Primary care low risk Primary care high risk 
            OR se p OR se p 
Country    <0·0001   <0·0001 
 UK         1·00 · ·  1·00 · ·  
 Australia  0·90 0·12 0·441 1·15 0·13 0·217 
 New Zealand 0·82 0·11 0·128 0·85 0·09 0·138 
 Ireland    1·07 0·14 0·626 1·11 0·12 0·363 
 Canada     0·69 0·09 0·005 0·85 0·09 0·138 
 Spain      0·55*** 0·07 <0·0001 0·77 0·08 0·016 
 Belgium    0·44*** 0·06 <0·0001 0·71** 0·08 0·002 
 Poland     0·75 0·10 0·036 1·04 0·12 0·757 
Age    0·3594   0·246 
 18-24      1·00 · ·  1·00 · ·  
 25-34      1·08 0·13 0·504 0·97 0·10 0·773 
 35-44      1·20 0·15 0·133 1·17 0·12 0·131 
 45-54      1·24 0·16 0·084 1·04 0·11 0·706 
 55-65 (55-59 Poland 
only) 1·28 0·18 0·077 1·04 0·12 0·763 
Gender        
 Male       1·00 · ·  1·00 · ·  
 Female     1·05 0·07 0·468 0·79*** 0·04 <0·0001 
Working status       
 Working    1·00 · ·  1·00 · ·  
Not working 0·92 0·08 0·374 0·87 0·06 0·059 
SES    0·264   0·989 
 A          1·00 · ·  1·00 · ·  
 B          1·17 0·14 0·200 1·04 0·10 0·725 
 C1         1·01 0·12 0·939 1·00 0·10 0·996 
 C2         0·98 0·13 0·873 0·99 0·11 0·913 
 D          1·21 0·21 0·259 1·04 0·15 0·766 
 E         0·93 0·13 0·611 1·04 0·13 0·747 
Faith    0·061   0·334 
 Muslim     0·55* 0·15 0·026 1·03 0·26 0·901 
 Christian  1·00 · ·  1·00 · ·  
 Jewish     0·56 0·23 0·159 0·58 0·21 0·124 
 Hindu      1·19 0·45 0·653 1·19 0·36 0·566 
 Buddhist   1·07 0·35 0·831 0·65 0·16 0·084 
 Other      1·11 0·08 0·139 0·99 0·06 0·836 
Education   0·158   0·749 
 No completed 
education 1·00 · ·  1·00 · ·  
 Primary education 
(ISCED 1) 0·63 0·31 0·343 0·69 0·31 0·406 
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Variable             Primary care low risk Primary care high risk 
            OR se p OR se p 
 
Lower secondary 
education (ISCED 2) 0·75 0·29 0·458 0·94 0·33 0·850 
 
Upper secondary 
education (ISCED 3) 0·81 0·31 0·574 0·92 0·32 0·810 
 
Post-secondary 
including pre-
vocational or 
vocational education 
but not tertiary 0·91 0·35 0·814 0·88 0·31 0·704 
 
Tertiary education first 
level (ISCED 5) 0·99 0·38 0·974 0·84 0·29 0·616 
 
Tertiary education 
advanced level 
(ISCED 6) 1·08 0·50 0·868 1·03 0·42 0·940 
Number of children in household   0·733   0·921 
 None       1·00 · ·  1·00 · ·  
 Only younger children 1·06 0·14 0·672 0·94 0·10 0·593 
 Only older children 0·94 0·08 0·462 0·99 0·07 0·844 
 
Older and younger 
children 1·08 0·17 0·620 0·93 0·12 0·583 
Marital status    0·268   0·036 
 Single (never married) 1·00 · ·  1·00 · ·  
 Living with partner 1·00 0·10 0·972 1·05 0·09 0·578  
Married /Civil 
partnership 0·93 0·09 0·456 1·01 0·08 0·899 
 Separated  1·07 0·31 0·826 1·61 0·41 0·061  
Divorced   0·89 0·15 0·491 1·16 0·17 0·288  
Widowed    1·32 0·48 0·436 2·40** 0·75 0·005  
Prefer not to say 0·25 0·14 0·017 0·56 0·32 0·311 
Knowledge about pandemics   <0·0001   < 0·0001 
 Yes 1·00 · ·  1·00 · ·  
Just a little 0·92 0·08 0·294 0·80** 0·06 0·001 
No 0·59*** 0·05 <0·0001 0·61*** 0·05 <0·0001 
ICU experience       
 No 1·00 · ·  1·00 · ·  
Yes 1·17 0·08 0·017 1·25*** 0·07 <0·0001 
Perceived health       
 Poor       1·00 · ·  1·00 · ·  
Good       1·07 0·09 0·439 1·11 0·08 0·131 
Trust in GP    <0·0001   <0·0001 
 Disagree  1·00 · ·  1·00 · ·  
 Neutral    2·02*** 0·24 <0·0001 1·67*** 0·19 <0·0001 
 Agree 3·18*** 0·36 <0·0001 2·15*** 0·23 <0·0001 
Trust in government   <0·0001   <0·0001 
 Low        1·00 · ·  1·00 · ·  
Neutral    1·74*** 0·21 <0·0001 2·00*** 0·24 <0·0001 
High       2·58*** 0·35 <0·0001 3·10*** 0·39 <0·0001 
Therapeutic misconception   <0·0001   < 0·0001 
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Variable             Primary care low risk Primary care high risk 
            OR se p OR se p 
 Low        1·00 · ·  1·00 · ·  
Neutral    2·54*** 0·32 <0·0001 1·45** 0·18 0·003 
High       8·82*** 1·18 <0·0001 2·72*** 0·35 <0·0001 
Access to new medication      0·0124 
 Disagree    1·00 · ·  
 Neutral       1·19 0·08 0·014 
 Agree/    1·22** 0·09 0·005 
 
Note: OR=Odds ratio; se = Standard error; *p<0·05, **p<0·01, ***p<0·001 
Estimates obtained from multiple ordinal regression models 
  
 27 
Table 3: Consent preferences for inclusion in low risk study in primary care during an influenza 
pandemic 
 First choice Second choice Third choice 
 All Willing* All Willin
g 
All  Willin
g 
Automatic inclusion: I lude e 
auto ati ally  
  
587 
(8·63) 
461 
(9·78) 
598 
(8·79) 
466 
(9·88) 
4404 
(64·73) 
3196 
(67·78) 
Opt-out: I lude e auto ati ally, ut 
remind me of the study when I get the 
medicine and give me a chance to opt 
out ·  
1740 
(25·57) 
1371 
(29·08) 
4000 
(58·79) 
2841 
(60·25) 
317 
(4·66) 
232 
(4·92) 
Opt-i : O ly sig  e up whe  I a  due to 
get the edi i e · 
 
3972 
(58·38) 
2742 
(58·15) 
1502 
(22·07) 
1169 
(24·79) 
724 
(10·64) 
602 
(12·77) 
No option preferred 
 
505 
(7·42) 
141 
(2·99) 
704 
(10·35) 
239 
(5·07) 
1359 
(19·97) 
685 
(14·53) 
*Proportion of respondents who indicated “agree” or “strongly agree” when asked whether they would be willing 
to take part in he primary care low risk scenario (4715 of 6804, 69·3%) 
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Table 4: Factors predictive of willingness to engage with alternate consent models in low risk primary 
care including only participants who were “willing to take part” 
 Variable OR se p 
Country    0·006 
 UK         1·00 · ·  
  Australia  0·58 0·17 0·059 
  New Zealand 0·78 0·25 0·441 
  Ireland    1·53 0·55 0·231 
  Canada     1·20 0·43 0·615 
  Spain      0·54* 0·16 0·035 
  Belgium    0·85 0·26 0·590 
  Poland     1·59 0·58 0·205 
Gender     
 Male       1·00 · ·  
  Female     0·91 0·15 0·568 
SES    0·006 
 A          1·00 · ·  
  B          1·00 0·33 0·995 
  C1         0·88 0·29 0·702 
  C2         0·71 0·25 0·331 
  D          0·41* 0·15 0·013 
  E         1·28 0·47 0·511 
Education    0·290 
 No completed education 1·00 · ·  
  Primary education (ISCED 1) 0·72 0·69 0·735 
  Lower secondary education (ISCED 2) 1·82 1·46 0·456 
  Upper secondary education (ISCED 3) 2·00 1·56 0·377 
  Post-secondary (incl. pre-vocational or vocational) 3·19 2·56 0·148 
  Tertiary education – first level (ISCED 5) 2·03 1·58 0·363 
  Tertiary education – advanced level (ISCED 6) 2·98 3·16 0·304 
  Prefer not to say 1·30 1·70 0·839 
ICU experience     
 No 1·00 · ·  
  Yes        1·85***  0·32 <0·001 
Illness experience     
 No         1·00 · ·  
  Yes        0·73 0·20 0·254 
Number of children in 
household    0·993 
 0          1·00 · ·  
  1          1·06 0·23 0·980 
  2          0·98 0·24 0·942 
  3 +         0·98 0·0·34 0·948 
Faith    0·219 
 Muslim     0·34* 0·17 0·033 
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 Variable OR se p 
  Christian  1·00 · ·  
  Jewish     0·57 0·60 0·593 
  Hindu      1·80 1·86 0·571 
  Other      1·08 0·18 0·659 
Knowledge of pandemics    0·011 
 A great deal/ fair amount 1·00 · ·  
  Just a little 0·89 0·19 0·595 
  Hear of but know nothing about/ never heard of 0·55**  0·13 0·009 
Trust in government    <0·001 
 Low        1·00 · ·  
  Neutral    3·52*** 1·02 <0·001 
  High       3·17***  0·97 <0·001 
Therapeutic 
misconception    0·782 
  
  
Low        1·00 · ·  
Neutral    1·37 0·62 0·493 
High       1·29 0·58 0·571 
Note: OR=Odds ratio; se = Standard error; *p<0·05, **p<0·01, ***p<0·001 
Estimates obtained from multiple logistic regression model 
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Table 5: Factors predictive of willingness to participate in low and higher risk pandemic-relevant studies 
in ICU 
Variable             ICU low risk ICU high risk 
            OR se p OR se p 
Country    <0·0001   <0·0001 
 UK         1·00 · ·  1·00 · ·  
 Australia  1·22 0·16 0·125 1·12 0·13 0·364 
 New Zealand 0·98 0·13 0·863 1·02 0·12 0·877 
 Ireland    1·30* 0·17 0·047 1·19 0·14 0·152 
 Canada     0·85 0·11 0·209 0·99 0·12 0·923 
 Spain      0·68** 0·09 0·003 0·58*** 0·07 <0·0001 
 Belgium    0·77* 0·10 0·043 0·74* 0·09 0·012 
 Poland     0·89 0·12 0·392 0·76* 0·10 0·028 
Age    0·117   0·013 
 18-24      1·00 · ·  1·00 · ·  
 25-34      1·24 0·14 0·069 1·07 0·12 0·547 
 35-44      1·18 0·14 0·159 1·33* 0·15 0·011 
 45-54      1·30* 0·16 0·036 1·36** 0·16 0·008 
 55-65 (55-59 Poland 
only) 1·06 0·15 0·660 1·37* 0·17 0·013 
Gender        
 Male       1·00 · ·  1·00 · ·  
 Female     0·93 0·06 0·254 0·95 0·06 0·407 
Working status       
 Working    1·00 · ·  1·00 · ·  
Not working 0·98 0·09 0·801 1·01 0·08 0·906 
SES    0·0181   0·0786 
 A          1·00 · ·  1·00 · ·  
 B          1·31* 0·16 0·021 1·30* 0·14 0·015 
 C1         1·17 0·14 0·195 1·15 0·13 0·198 
 C2         1·05 0·14 0·693 1·15 0·14 0·235 
 D          1·07 0·17 0·690 1·17 0·18 0·305 
 E         0·87 0·12 0·343 0·97 0·13 0·810 
Faith    0·223   0·013 
 Muslim     0·76 0·22 0·340 0·59* 0·15 0·042 
 Christian  1·00 · ·  1·00 · ·  
 Jewish     0·48 0·18 0·056 0·54 0·22 0·128 
 Hindu      0·66 0·21 0·197 0·76 0·25 0·405 
 Buddhist   0·72 0·22 0·279 0·60 0·17 0·063 
 Other      0·98 0·07 0·731 1·10 0·07 0·134 
Education   0·131   0·090 
 
No completed education 1·00 · ·  1·00 · ·  
 Primary education 
(ISCED 1) 0·71 0·34 0·482 0·47 0·22 0·099 
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Variable             ICU low risk ICU high risk 
            OR se p OR se p 
 
Lower secondary 
education (ISCED 2) 0·97 0·37 0·939 0·90 0·33 0·773 
 
Upper secondary 
education (ISCED 3) 0·79 0·30 0·525 0·78 0·28 0·492 
 
Post-secondary including 
pre-vocational or 
vocational education but 
not tertiary 0·89 0·34 0·769 0·78 0·28 0·500 
 
Tertiary education first 
level (ISCED 5) 1·01 0·38 0·970 0·92 0·33 0·812 
 
Tertiary education 
advanced level (ISCED 
6) 1·04 0·47 0·939 1·10 0·48 0·817 
Number of children in household   0·401   0·3586 
 None       1·00 · ·  1·00 · ·  
 Only younger children 0·83 0·10 0·128 0·84 0·10 0·145 
 Only older children 0·92 0·08 0·347 0·98 0·08 0·822 
 
Older and younger 
children 0·87 0·13 0·358 0·84 0·12 0·206 
Marital status    0·396   0·1500 
 Single (never married) 1·00 · ·  1·00 · ·  
 Living with partner 0·89 0·09 0·274 0·91 0·09 0·336  
Married /Civil 
partnership 1·06 0·10 0·545 0·94 0·08 0·500 
 Separated  1·52 0·48 0·189 1·20 0·33 0·512  
Divorced   1·16 0·19 0·380 1·13 0·18 0·453  
Widowed    1·46 0·51 0·275 1·81 0·61 0·078  
Prefer not to say 0·88 0·56 0·844 0·37 0·21 0·077 
Knowledge about pandemics   <0·0001   <0·0001 
 Yes 1·00 · ·  1·00 · ·  
Just a little 0·86 0·07 0·0560 0·74*** 0·06 0·0001 
No 0·60*** 0·06 <0·0001 0·55*** 0·05 <0·0001 
ICU experience       
 No 1·00 · . 1·00 · ·  
Yes 1·16 0·08 0·024 1·20** 0·07 0·003 
Perceived health       
 Poor       1·00 · ·  1·00 · ·  
Good       0·97 0·08 0·699 1·26** 0·10 0·002 
Trust in GP    <0·0001   <0·0001 
 Disagree  1·00 · ·  1·00 · ·  
 Neutral    1·34** 0·16 0·016 1·63*** 0·20 <0·0001 
 Agree 1·76*** 0·20 <0·0001 2·27*** 0·25 <0·0001 
Trust in government   <0·0001   <0·0001 
 Low        1·00 · ·  1·00 · ·  
Neutral    2·21*** 0·27 <0·0001 2·66*** 0·32 <0·0001 
High       3·72*** 0·50 <0·0001 4·06*** 0·53 <0·0001 
Therapeutic misconception   <0·0001   <0·0001 
 Low        1·00 · ·  1·00 · ·  
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Variable             ICU low risk ICU high risk 
            OR se p OR se p 
Neutral    1·74*** 0·22 <0·0001 0·95 0·12 0·680 
High       4·35*** 0·59 <0·0001 1·58*** 0·21 0·001 
Access to new medication      <0·0001 
 Disagree    1·00 · ·  
 Neutral       1·48*** 0·11 <0·0001 
 Agree/    4·85*** 0·41 <0·0001 
Note: OR=Odds ratio; se = Standard error; *p<0·05, **p<0·01, ***p<0·001 
Estimates obtained from multiple ordinal logistic regression models 
  
 33 
Table 6: Consent preferences for inclusion in low risk study in ICU during an influenza pandemic 
 First choice Second choice Third choice Fourth choice  
 All Willing* All Willing All Willing All Willing 
Deferred consent (family) 
Include me immediately, family 
decides later if that’s ok  
1163 
(17·09) 
958 
(20·04) 
2236 
32·86) 
1690 
(35·36) 
1620 
(23·81) 
1223 
(25·59) 
741 
(10·89) 
499 
(10·44) 
Deferred consent (doctor): 
Include me immediately, doctor 
decides later if that’s ok 
1637 
(24·06) 
1343 
(28·09) 
2077 
(30·53) 
1582 
(33·10) 
1809 
(27·78) 
1266 
(26·49) 
294 
(4·32) 
221 
(4·62) 
Automatic enrolment: Include 
me immediately, don’t ask my 
or anyone’s consent  
718 
(10·55) 
592 
(12·38) 
945 
(13·89) 
724 
(15·15) 
1269 
(18·65) 
995 
(20·82) 
2649 
(38·93) 
1945 
(40·69) 
Opt-in: Don’t include me until a 
family member says it’s ok 
2623 
(38·55) 
1686 
(35·27) 
621 
(9·13) 
458 
(9·58) 
1056 
(15·52) 
884 
(18·49) 
1576 
 
(23·16) 
1344 
(28·12) 
No preference recorded 
 
663 
(9·74) 
201 
(4·21) 
925 
(13·59) 
326 
(6·82) 
1050 
(15·43) 
412 
(8·62) 
1544   
(22·69) 
771 
(16·13) 
*Proportion of respondents who indicated “agree” or “strongly agree” when asked whether they would be willing to take 
part in the primary care low risk scenario
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Table 7 Binary logistic regression of participant consent preferences for low risk ICU study during an influenza 1 
pandemic including only participants who were willing to participate 2 
 Variable            OR se p 
Country    0·004 
 UK         1·00 · ·  
  Australia  1·25 0·33 0·399 
  New Zealand 1·47 0·42 0·185 
  Ireland    2·67** 0·86 0·002 
  Canada     1·16 0·32 0·583 
  Spain      0·83 0·21 0·478 
  Belgium    0·74 0·18 0·205 
  Poland     1·27 0·34 0·368 
Age    0·580 
 18-24      1·00 · ·  
  25-34      0·86 0·21 0·525 
  35-44      0·80 0·21 0·391 
  45-54      
1·0 
6 0·28 0·832 
  55-65 (55-59 Poland only) 0·77 0·21 0·347 
Gender     
 Male       1·00 · ·  
  Female     0·69** 0·10 0·008 
SES    0·024 
 A          1·00 · ·  
  B          1·08 0·29 0·763 
  C1         0·85 0·22 0·538 
  C2         0·71 0·20 0·223 
  D          0·81 0·28 0·536 
  E         1·74 0·57 0·085 
Education    0·013 
 No completed education 1·00 · ·  
  Primary education (ISCED 1) 0·60 0·51 0·550 
  Lower secondary education (ISCED 2) 2·19 1·49 0·250 
  Upper secondary education (ISCED 3) 2·28 1·50 0·210 
  
Post-secondary including pre-vocational or vocational 
education but not tertiary 2·50 0·1·68 0·173 
  Tertiary education – first level (ISCED 5) 1·88 1·22 0·173 
  Tertiary education – advanced level (ISCED 6) 0·85 0·64 0·834 
  Prefer not to say 0·45 0·41 0·385 
ICU Experience     
 No 1·00 · ·  
  Yes        2·00** 0·29 <0·001 
Illness Experience     
 No         1·00 · ·  
  Yes        0·85 0·21 0·524 
Perceived health     
 Poor       1·00 · ·  
  Good       1·13 0·20 0·492 
Number of people in 
household    0·693 
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 Variable            OR se p 
  
  
1   1·00 · ·  
2   0·66 0·17 0·109 
3   0·74 0·21 0·296 
  4   0·72 0·22 0·280 
  5   0·65 0·25 0·270 
  6   1·21 0·80 0·769 
  7   1·39 1·49 0·760 
    ·  ·  
Number of children    0·972 
 0          1·00 · ·  
  1          0·92 0·19 0·676 
  2          0·97 0·27 0·918 
  3 +         1·05 0·45 0·906 
Marital status     
 On their own 1·00 · ·  
  Living with someone 1·68** 0·29 0·003 
Knowledge of 
pandemics    0·248 
 A great deal/ fair amount 1·00 · ·  
  Just a little 0·97 0·17 0·875 
  Hear of but know nothing about/ never heard of 0·76 0·15 0·154 
Trust in government    0·003 
 Low        1·00 · ·  
  Neutral    2·33** 0·62 0·001 
  High       2·54* 0·71 0·001 
Therapeutic 
misconception    0·479 
 Low        1·00 · ·  
  Neutral    1·36 0·45 0·356 
  High       1·47 0·48 0·238 
 3 
Note: OR=Odds ratio; se = Standard error; *p<0·05, **p<0·01, ***p<0·001 4 
Estimates obtained from multiple logistic regression model 5 
  6 
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Table 8: Factors predictive of willingness to donate excess from clinical samples for pandemic-relevant research 7 
           Overall 
            OR se p 
Country    <0·001 
 UK         1·00 · ·  
 Australia  0·66 0·10 0·004 
 New Zealand 0·69* 0·10 0·012 
 Ireland    0·83 0·12 0·201 
 Canada     0·69* 0·10 0·014 
 Spain      0·46*** 0·07 <0·001 
 Belgium    0·71* 0·11 0·024 
  Poland     0·48*** 0·07 <0·001 
Age    <0·001 
 18-24      1·00 · ·  
 25-34      1·34* 0·16 0·011 
 35-44      1·55*** 0·18 <0·001 
 45-54      1·98*** 0·24 <0·001 
  55-65 (55-59 Poland only) 2·29*** 0·31 <0·001 
Gender     
 Male       1·00 · ·  
  Female     1·04 0·07 0·585 
Employment status     
 Working    1·00 · ·  
  Not working 1·07 0·10 0·488 
SES    0·0024 
 A          1·00 · ·  
 B          1·23 0·16 0·127 
 C1         1·05 0·14 0·705 
 C2         0·81 0·11 0·142 
 D          0·81 0·14 0·208 
  E         0·83 0·13 0·217 
Faith    0·0204 
 Muslim     0·59 0·17 0·063 
 Christian  1·00 · ·  
 Jewish     1·19 0·61 0·731 
 Hindu      0·57 0·18 0·082 
 Buddhist   0·92 0·30 0·801 
  Other      1·18* 0·09 0·033 
Knowledge about 
pandemics    <0·001 
 A great deal/ fair amount 1·00 · ·  
 Just a little 0·96 0·09 0·625 
  Hear of but know nothing about/ never heard of 0·70*** 0·07 <0·001 
ICU Experience     
 No 1·00 · ·  
  Yes 1·34 0·10 <0·001 
Perceived overall health     
 Poor       1·00 · ·  
  Good       1·15 0·10 0·106 
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Trust in GP    <0·001 
 Strongly disagree/disagree 1·00 · ·  
 Neutral    1·10 0·14 0·472 
  Agree/strongly agree 1·95*** 0·24 <0·001 
Trust in government    <0·001 
 Low        1·00 · ·  
 Neutral    2·40*** 0·31 <0·001 
  High       4·84*** 0·71 <0·001 
Therapeutic misconception   <0·001 
 Low        1·00 · ·  
 Neutral    1·00 0·15 0·989 
  High       1·60** 0·25 0·002 
 8 
Note: OR=Odds ratio; se = Standard error; *p<0·05, **p<0·01, ***p<0·001 9 
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